Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting (DART(®)) bispecific molecule against P-cadherin and CD3 that demonstrates...

Descripción completa

Detalles Bibliográficos
Autores principales: Root, Adam R., Cao, Wei, Li, Bilian, LaPan, Peter, Meade, Caryl, Sanford, Jocelyn, Jin, Macy, O’Sullivan, Cliona, Cummins, Emma, Lambert, Matthew, Sheehan, Alfredo D., Ma, Weijun, Gatto, Scott, Kerns, Kelvin, Lam, Khetemenee, D’Antona, Aaron M., Zhu, Lily, Brady, William A., Benard, Susan, King, Amy, He, Tao, Racie, Lisa, Arai, Maya, Barrett, Dianah, Stochaj, Wayne, LaVallie, Edward R., Apgar, James R., Svenson, Kristine, Mosyak, Lidia, Yang, Yinhua, Chichili, Gurunadh R., Liu, Liqin, Li, Hua, Burke, Steve, Johnson, Syd, Alderson, Ralph, Finlay, William J. J., Lin, Laura, Olland, Stéphane, Somers, William, Bonvini, Ezio, Gerber, Hans-Peter, May, Chad, Moore, Paul A., Tchistiakova, Lioudmila, Bloom, Laird
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698862/
https://www.ncbi.nlm.nih.gov/pubmed/31557987
http://dx.doi.org/10.3390/antib5010006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698862/
https://www.ncbi.nlm.nih.gov/pubmed/31557987
http://dx.doi.org/10.3390/antib5010006

Ejemplares similares